MARKSANS
OVERVALUEDMarksans Pharma Limited
Healthcare · NSE
↓ 29.6% vs fair value
52W Low
₹155
+36.8% from low
52W High
₹271
-21.7% from high
Valuation Gauge
Current Price
₹212
Fair Value
₹164
Fair Value Analysis
₹164
Based on free cash flow projections and balance sheet strength analysis and earnings growth potential for Healthcare sector companies | Sector-cheap: P/E at 24th percentile vs sector peers. | CAUTION: ROCE declining (latest 19.0%) — returns on capital are falling; verify this isn't a value trap.
Cash Flow Analysis
40% weight
Balance Sheet Value
20% weight
Growth Valuation
40% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Financially Healthy
Profitability
ROE of 13.5% is acceptable for Healthcare sector (benchmark: 15%)
Debt & Leverage
D/E ratio of 0.1x is well within the Healthcare sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 26.2x trades at a 84% discount to Healthcare sector median (160x) — attractively valued
Cash Flow
FCF margin of 1.3% — very thin despite positive FCF (₹34 Cr)
Earnings Growth
5yr EPS CAGR of 27.3% is in line with the Healthcare sector average of 18.7%
Dividend
Dividend yield of 0.4% is symbolic — low but positive
Company Health Timeline
10-year financial health at a glance
Sentiment Trend — Last 30 Days
Historical Returns
Key Ratios & Growth
FCF Yield
1.7%
Free cash flow / market cap
Revenue Growth (YoY)
+10.6%
Year-on-year revenue change
Profit Growth (YoY)
+8.6%
Year-on-year PAT change
Operating Cash Flow
₹207 Cr
TTM cash from operations
Key Financials
EPS (TTM)
₹8
P/E Ratio
26.2x
P/B Ratio
3.5x
ROE
13.5%
ROCE
18.7%
Debt / Equity
0.12x
Beta
0.98
Div Yield
0.4%
FCF (Cr)
₹34 Cr
Revenue (Cr)
₹2,614 Cr
EPS Growth 5Y
27.3%
Mkt Cap (Cr)
₹9,401 Cr
52W High
₹270.7
52W Low
₹155
Book Value/Share
₹59
Financial History
| Period | Revenue | Op Profit | OPM% | PAT | EPS |
|---|---|---|---|---|---|
| TTM | ₹2.8K Cr | ₹532 Cr | 19.0% | ₹362 Cr | ₹7.96 |
| 2025-03-31 | ₹2.6K Cr | ₹529 Cr | 20.0% | ₹383 Cr | ₹8.40 |
| 2024-03-31 | ₹2.2K Cr | ₹459 Cr | 21.0% | ₹315 Cr | ₹6.92 |
| 2023-03-31 | ₹1.9K Cr | ₹340 Cr | 18.0% | ₹265 Cr | ₹5.88 |
| 2022-03-31 | ₹1.5K Cr | ₹259 Cr | 17.0% | ₹187 Cr | ₹4.51 |
| 2021-03-31 | ₹1.4K Cr | ₹340 Cr | 25.0% | ₹239 Cr | ₹5.76 |
| 2020-03-31 | ₹1.1K Cr | ₹192 Cr | 17.0% | ₹121 Cr | ₹2.95 |
| 2019-03-31 | ₹1.0K Cr | ₹132 Cr | 13.0% | ₹80 Cr | ₹1.87 |
| 2018-03-31 | ₹913 Cr | ₹78 Cr | 9.0% | ₹36 Cr | ₹0.80 |
| 2017-03-31 | ₹767 Cr | ₹45 Cr | 6.0% | ₹11 Cr | ₹0.22 |
| 2016-03-31 | ₹893 Cr | ₹136 Cr | 15.0% | ₹83 Cr | ₹1.92 |
| 2015-03-31 | ₹797 Cr | ₹185 Cr | 23.0% | ₹112 Cr | ₹2.67 |
| 2014-03-31 | ₹630 Cr | ₹118 Cr | 19.0% | ₹74 Cr | ₹1.87 |
Compounded Growth Rates
Sales Growth
Profit Growth
EPS Growth
Peer Comparison
Healthcare| Stock | Price | Fair Value | MoS% | P/E | ROE | Signal |
|---|---|---|---|---|---|---|
Anlon Healthcare Limited | ₹13.9 | ₹50.7 | +72.6% | 20.5 | 7.3% | UNDERVALUED |
Alpa Laboratories Limited | ₹69.8 | ₹196.4 | +64.5% | 12.8 | 13.4% | FAIRLY_VALUED |
Aster DM Healthcare | ₹755.4 | ₹1,585.8 | +52.4% | 117.6 | 7.9% | UNDERVALUED |
Vimta Labs Limited | ₹453 | ₹722.6 | +37.3% | 26.2 | 18.6% | UNDERVALUED |
Unichem Laboratories Limited | ₹372.6 | ₹592.5 | +37.1% | 8.9 | 12.1% | FAIRLY_VALUED |
Dishman Carbogen Amcis Limited | ₹195.5 | ₹281.2 | +30.5% | 25.6 | 1.9% | FAIRLY_VALUED |
Indraprastha Medical Corporation Limited | ₹358.2 | ₹462.6 | +22.6% | 18.5 | 20.6% | UNDERVALUED |
Morepen Laboratories Limited | ₹43 | ₹52.8 | +18.5% | 23.3 | 10.8% | FAIRLY_VALUED |
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant